|
PDCD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.09360001241544E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.14769999971199E-07 |
| Normal-vs-Stage2 |
1.148780E-01 |
| Normal-vs-Stage3 |
7.58749996165875E-09 |
| Normal-vs-Stage4 |
3.05789948917834E-10 |
| Stage1-vs-Stage2 |
3.764400E-01 |
| Stage1-vs-Stage3 |
2.068400E-02 |
| Stage1-vs-Stage4 |
1.501010E-03 |
| Stage2-vs-Stage3 |
4.355800E-02 |
| Stage2-vs-Stage4 |
9.836300E-03 |
| Stage3-vs-Stage4 |
3.535200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.70790004150723E-09 |
| Normal-vs-AfricanAmerican |
2.555100E-03 |
| Normal-vs-Asian |
1.155490E-03 |
| Caucasian-vs-AfricanAmerican |
7.099800E-01 |
| Caucasian-vs-Asian |
2.126600E-01 |
| AfricanAmerican-vs-Asian |
2.657000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63031000000036E-05 |
| Normal-vs-Female |
1.27020000073585E-08 |
| Male-vs-Female |
8.618600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.87549999997039E-06 |
| Normal-vs-Age(41-60Yrs) |
3.07259999998699E-07 |
| Normal-vs-Age(61-80Yrs) |
8.06650000018116E-07 |
| Normal-vs-Age(81-100Yrs) |
3.381900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.235400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.183600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.196400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.918600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.880400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.381600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.699600E-03 |
| Classical-VS-Follicular |
3.894800E-01 |
| Classical-VS-Other |
8.135000E-01 |
| Classical-VS-Normal |
3.75039999944704E-07 |
| Tall-VS-Follicular |
1.604540E-03 |
| Tall-VS-Other |
2.731000E-01 |
| Tall-VS-Normal |
6.12149997358813E-10 |
| Follicular-VS-Other |
9.178200E-01 |
| Follicular-VS-Normal |
1.247660E-02 |
| Other-VS-Normal |
3.478400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.35709999999445E-05 |
| Normal-vs-N1 |
1.50550000022065E-07 |
| N0-vs-N1 |
2.766200E-02 |
|
|
